SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
E_K_S
Spekulatius
To: E_K_S who wrote (68522)9/2/2021 11:00:35 AM
From: diegosan2 Recommendations   of 78778
 
The FDA is concerned about JAK inhibitors in inflammatory diseases, brought about by long term studies of PFE's Xeljanz. Not specifically ABBV, but as Humira is nearing patent expiration, their new drug in the JAK inhibitor class, Rinvoq, might not now to be able to fill the revenue gap. Kudos to DewDiligence:
investorshub.advfn.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News